<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375075</url>
  </required_header>
  <id_info>
    <org_study_id>13049</org_study_id>
    <secondary_id>I1V-JE-EIAE</secondary_id>
    <nct_id>NCT01375075</nct_id>
  </id_info>
  <brief_title>A Study of LY2484595 in Japanese Subjects</brief_title>
  <official_title>A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if 12 weeks of treatment with LY2484595
      administered as a monotherapy will significantly increase high-density lipoprotein
      cholesterol (HDL-C) and decrease low-density lipoprotein cholesterol (LDL-C) in Japanese
      participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline to 12 Weeks in High Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 and Placebo</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percent change from baseline = 100*(post-baseline assessment - baseline assessment)/baseline assessment. Higher values in the percent change from baseline represented an improvement for HDL-C and lower values in the percent change from baseline represented an improvement for LDL-C. Least Squares (LS) mean was adjusted for baseline value of the variable analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Atorvastatin</measure>
    <time_frame>Baseline, Weeks 2, 4, and 8</time_frame>
    <description>Percent change from baseline = 100*(post-baseline assessment - baseline assessment)/baseline assessment. An increase in the percent change from baseline represented an improvement for HDL-C and a decrease in the percent change from baseline represents an improvement for LDL-C. LS mean was adjusted for baseline value of the variable analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area Under the Curve (AUC) of LY2484595 and Atorvastatin</measure>
    <time_frame>Weeks 2, 4, 8, 12 (predose and postdose), and Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number and Severity of Episodes of Rashes at Any Time From Baseline Through Week 12</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>All rash cases were adjudicated by a central dermatologist blinded to treatment assignment according to a study-specific Clinical Events Committee (CEC) charter. Rash events were assessed according to clinical relevance (severity). Categories included high risk, low risk, not a relevant dermatosis, or insufficient documentation for determination. High risk rashes included anaphylaxis, toxic epidermal necrolysis, Stevens Johnson Syndrome, Drug Reaction with Eosinophilia and System Symptoms (DRESS), urticaria/angioedema, vasculitis, erythroderma, and lupus-like reaction. All other rashes were considered low risk or not a relevant dermatosis per the Investigator's clinical opinion. A participant could be reported in multiple categories.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Weeks in Blood Pressure</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Blood pressure reported as systolic blood pressure (SBP) and diastolic blood pressure (DBP).
LS mean was adjusted for baseline value of the variable analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Weeks in Aldosterone</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>LS mean was adjusted for baseline value of the variable analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Weeks in Plasma Renin Activity</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>LS mean was adjusted for baseline value of the variable analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Weeks in Serum Sodium</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>LS mean was adjusted for baseline value of the variable analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Weeks in Serum Bicarbonate</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>LS mean was adjusted for baseline value of the variable analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Myopathy and Liver Injury Events</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Myopathy events were considered muscle-related treatment emergent adverse events (TEAEs) and liver injury events were considered hepatic disorder-related TEAEs reported per Medical Dictionary for Regulatory Activities (MedDRA). An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs were newly occurring AEs or AEs worsening after first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Highly-Sensitive C-Reactive Protein (hsCRP)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>LS mean was adjusted for baseline value of the variable analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Plasma Cholesteryl Ester Transfer Protein (CETP) Activity</measure>
    <time_frame>Baseline, Weeks 4, 8, and 12</time_frame>
    <description>Plasma CETP activity assay employed a fluorometric method to determine the CETP transfer activity. Percent change from baseline = 100*(post-baseline assessment - baseline assessment)/baseline assessment. An increase in the percent change from baseline represented an improvement. LS mean was adjusted for baseline value of the variable analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma CETP Mass</measure>
    <time_frame>Baseline, Weeks 4, 8, and 12</time_frame>
    <description>Plasma CETP mass assay was a solid-phase enzyme-linked immunosorbent assay (ELISA) designated to measure human CETP mass which employed the quantitative enzyme immunoassay principle. An increase in plasma CETP mass represented an improvement. LS mean was adjusted for baseline value of the variable analyzed.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>30 milligrams (mg) LY2484595</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg LY2484595</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500 mg LY2484595</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administered orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg LY2484595 + 10 mg Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered orally once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2484595</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>100 mg LY2484595</arm_group_label>
    <arm_group_label>100 mg LY2484595 + 10 mg Atorvastatin</arm_group_label>
    <arm_group_label>30 milligrams (mg) LY2484595</arm_group_label>
    <arm_group_label>500 mg LY2484595</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>10 mg Atorvastatin</arm_group_label>
    <arm_group_label>100 mg LY2484595</arm_group_label>
    <arm_group_label>100 mg LY2484595 + 10 mg Atorvastatin</arm_group_label>
    <arm_group_label>30 milligrams (mg) LY2484595</arm_group_label>
    <arm_group_label>500 mg LY2484595</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>10 mg Atorvastatin</arm_group_label>
    <arm_group_label>100 mg LY2484595 + 10 mg Atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Have Low HDL-C or High LDL-C criteria as follows:

        Low HDL lipid criteria:

          -  HDL-C &lt;45 milligrams per deciliter (mg/dL) (men) and &lt;50 mg/dL (women), and

          -  LDL-C according to Japan Atherosclerosis Society (JAS) guidelines as follows:

               -  LDL-C &lt;190 mg/dL (0-1 risk factors)

               -  LDL-C &lt;160 mg/dL (2 risk factors)

               -  LDL-C &lt;130 mg/dL (3+ risk factors),and

          -  Fasting Triglycerides (TG) &lt;400 mg/dL

        or

        High LDL-C lipid criteria:

          -  HDL-C &lt;100 mg/dL, and

          -  LDL-C according to JAS guidelines as follows:

               -  LDL-C 100-190 mg/dL (0-1 risk factors)

               -  LDL-C 100-160 mg/dL (2 risk factors)

               -  LDL-C 100-130 mg/dL (3+ risk factors), and

          -  Fasting TG &lt;400 mg/dL

        Note: Subjects with diabetes regarded as 3+ risk factors

          -  Male subjects: Agree to use a reliable method of birth control during the study (and
             for 2 weeks following the last dose of study drug)

          -  Female subjects: 1) Women not of childbearing potential due to surgical sterilization
             (at least 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or
             tubal ligation) confirmed by medical history, or menopause. Menopausal women include
             women with either a) spontaneous amenorrhea for at least 12 months, not induced by a
             medical condition such as anorexia nervosa and not taking medications during the
             amenorrhea that induced the amenorrhea [for example, oral contraceptives, hormones,
             gonadotropin releasing hormone, anti-estrogens, selective estrogen receptor modulators
             (SERMs), or chemotherapy] or b) spontaneous amenorrhea for 6 to 12 months and a
             follicle-stimulating hormone (FSH) level greater than 40 milli-international units per
             milliliter (mIU/mL). or, 2) Women of child bearing potential who test negative for
             pregnancy at the time of enrollment based on a urine or serum pregnancy test and agree
             to use a reliable method of birth control during the study and for 2 weeks following
             the last dose of study drug

          -  Have given informed consent to participate in the study

        Exclusion Criteria:

          -  At screening, are currently enrolled in, or discontinued within the last 30 days from,
             a clinical trial involving an investigational product or unapproved use of a drug or
             device (other than the investigational product used in this study), or concurrently
             enrolled in any other type of medical research judged not to be scientifically or
             medically compatible with this study

          -  Have participated within 90 days prior to screening in any clinical trials of
             cholesteryl ester transfer protein (CETP) inhibitors (e.g., anacetrapib or
             dalcetrapib)

          -  Have completed or withdrawn from this study or have completed or withdrawn from any
             other study investigating LY2484595

          -  Are unable, unreliable, and/or unwilling to provide informed consent, make themselves
             available for the duration of the study, or will not abide by the procedures and study
             restrictions

          -  Have recent history of any clinically significant rash, history of any clinically
             severe drug-related rash, history of a chronic skin disorder (such as psoriasis,
             eczema or urticaria), history of significant skin hypersensitivities to household or
             cosmetic products, or allergens per the investigator, or presence of widespread
             tattoos or other skin condition that limits the assessment for rashes. Subjects who
             develop any rash during the Diet Lead-in/Washout Phase cannot be randomized

          -  Have or have had any clinical manifestation of coronary heart disease (CHD), such as
             stable or unstable angina, acute coronary syndrome, myocardial infarction, or a
             coronary revascularization procedure including stent placement, symptomatic carotid
             artery disease or symptomatic peripheral arterial disease. Subjects with a diagnosis
             of abdominal aortic aneurysm are excluded from this study

          -  Have systolic blood pressure (SBP) &gt;140 millimeters of mercury (mm Hg) or diastolic
             blood pressure (DBP) &gt;90 mm Hg as determined by the mean of 3 standardized
             measurements in the sitting position at randomization

          -  Have or have had documented hyperaldosteronism

          -  Have symptoms consistent with moderate or severe heart failure or are receiving
             treatment for symptomatic congestive heart failure (CHF) or known left ventricular
             ejection fraction (LVEF) &lt;35%. The absence of LVEF measurement does not prohibit entry
             into this study

          -  Have one of the following abnormalities: QTc prolongation [Bazett's corrected QT
             interval (QTcB)] of &gt;450 msec in male subjects or &gt;470 msec in female subjects, or
             abnormally wide QRS complexes (resulting from bundle branch blocks, intraventricular
             conduction delays, or pacemakers) or atrial fibrillation on screening
             electrocardiogram (ECG), previous history of QTc prolongation with another medication
             that required discontinuation, congenital long QT syndrome, previous history of
             ventricular tachycardia or unexplained syncope

          -  Have family history of long QT syndrome or sudden death likely secondary to
             ventricular arrhythmia

          -  Have active hepatobiliary disease, serologic evidence of past or active hepatitis B or
             C, or past or active gallbladder disease. Subjects who have been diagnosed with
             Gilbert syndrome or had a cholecystectomy greater than 90 days prior to screening can
             be included

          -  Have aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT),
             alkaline phosphatase (ALP), or total bilirubin &gt;1.5 times the upper limit of normal
             (ULN)

          -  Have a history or presence of a chronic muscular or neuromuscular disease including
             prior rhabdomyolysis or drug-induced myopathy or an unexplained/documented elevation
             in creatine kinase (CK) ≥3 times the ULN

          -  Have a history of discontinuation from statin, change of statin, or a dose reduction
             of statin due to history of hypersensitivity, intolerance or adverse effect. Have a
             history of increased hepatic enzymes associated with use of an
             hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin)

          -  Have a history of hypersensitivity or intolerance to drug preparations containing
             cholesteryl ester transfer protein (CETP) inhibitors, including but not limited to
             torcetrapib, anacetrapib, or dalcetrapib

          -  Have a hemoglobin A1c ≥8.0%; or use, plan to use, or are likely to require insulin
             during the course of the study. Diabetic subjects on an antidiabetic agent with lipid
             modifying effects must be on a stable dose for at least 30 days prior to screening

          -  Have a serum creatinine ≥2 mg/dL, or nephrotic syndrome, end stage renal disease and
             use renal replacement therapy such as hemodialysis or peritoneal dialysis

          -  Have hemoglobin &lt;10 grams per deciliter (g/dL) in women and &lt;11 g/dL in men

          -  Have current uncontrolled active inflammatory condition or infection which in the
             opinion of the investigator would influence a subject's ability to complete the study

          -  Have thyroid-stimulating hormone (TSH) levels outside normal reference range. Subjects
             who are clinically euthyroid, on stable thyroid replacement therapy for 60 days prior
             to screening, and are anticipated to remain on this dose throughout the trial period
             are acceptable exceptions to this criterion

          -  Are women who are lactating

          -  Have planned or are likely to require major surgery requiring anesthesia or
             hospitalization during the course of the study

          -  Have chronic alcohol or drug abuse or dependency

          -  Are currently under suspicion of having cancer or have had a history of cancer in the
             past 2 years, with the exception of excised superficial lesions such as basal cell
             carcinoma and squamous cell carcinoma of the skin

          -  Have history of human immunodeficiency virus (HIV) infection

          -  Have any other condition or abnormal laboratory value, which in the opinion of the
             investigator precludes the subject from providing informed consent

          -  Plan to use, are likely to require, or unwilling or unable to stop with adequate
             washout any prescription or over-the-counter (OTC) medication or health foods with the
             intent to treat serum lipids (LDL-C, HDL-C, triglycerides) including but not limited
             to these classes of drugs: statin, ezetimibe, bile acid sequestrant, eicosapentaenoic
             acid (EPA). Subjects taking probucol, fibrate or nicotinic agents within 8 weeks
             before screening are excluded from the study

          -  Are currently using, plan to use, or are likely to require during the course of the
             study systemic corticosteroids; or anabolic agents other than stable doses of
             estrogen, estrogen/progestin, or testosterone replacement therapy

          -  Are currently using, plan to use, or are likely to require during the course of the
             study, more than the occasional use (i.e., once every other week) of stimulant
             laxatives (e.g., bisacodyl), osmotic laxatives (e.g., milk of magnesia), or castor oil

          -  Use of any immunosuppressive therapy within 60 days prior to screening or are likely
             to require immunosuppressive therapy during the course of the study

          -  Have received treatment within 30 days prior to the time of study entry with any drug
             or drugs that have not received regulatory approval for any indication

          -  Have plans to adopt diets with aggressive carbohydrate restrictions for weight loss.
             Currently use, have used within 60 days prior to screening, or plan to use during the
             trial period prescriptions or OTC formulations intended for weight loss

          -  Are currently using, have used within 60 days prior to screening, plan to use, or are
             likely to require during the course of the study, drugs or foods that are inducers
             (including rifampin and carbamazepine) or moderate or strong inhibitors of cytochrome
             P450 3A (including, ketoconazole, erythromycin and grapefruit juice); or strong
             inhibitors of the organic anion transporter polypeptide 1B1 (OATP1B1) transporter
             (including cyclosporine and rifampin). The drugs used in topical preparations are
             acceptable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <zip>660-0814</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kanagawa</city>
        <zip>231-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyoto</city>
        <zip>615-8125</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>560-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>111-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>June 15, 2011</study_first_submitted>
  <study_first_submitted_qc>June 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2011</study_first_posted>
  <results_first_submitted>February 18, 2018</results_first_submitted>
  <results_first_submitted_qc>March 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2018</results_first_posted>
  <disposition_first_submitted>May 24, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 24, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 1, 2012</disposition_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Evacetrapib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Prior to randomization, participants stopped lipid-related concomitant medications and started a diet therapy in accordance with the Japan Atherosclerosis Society guidelines for diagnosis and prevention of atherosclerotic cardiovascular disease.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>30 mg LY2484595</title>
          <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 30-milligram (mg) tablet</description>
        </group>
        <group group_id="P2">
          <title>100 mg LY2484595</title>
          <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 100-mg tablet</description>
        </group>
        <group group_id="P3">
          <title>500 mg LY2484595</title>
          <description>The following were administered orally once daily for 12 weeks:
Placebo (Atorvastatin): 1 capsule
LY2484595: five 100-mg tablets</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 5 tablets
Placebo (Atorvastatin): 1 capsule</description>
        </group>
        <group group_id="P5">
          <title>10 mg Atorvastatin</title>
          <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
Placebo (LY2484595): 5 tablets</description>
        </group>
        <group group_id="P6">
          <title>100 mg LY2484595 + 10 mg Atorvastatin</title>
          <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
LY2484595: A single 100-mg tablet
Placebo (LY2484595): 4 tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criterion Not Met</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>30 mg LY2484595</title>
          <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule LY2484595: A single 30-mg tablet</description>
        </group>
        <group group_id="B2">
          <title>100 mg LY2484595</title>
          <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 100-mg tablet</description>
        </group>
        <group group_id="B3">
          <title>500 mg LY2484595</title>
          <description>The following were administered orally once daily for 12 weeks:
Placebo (Atorvastatin): 1 capsule
LY2484595: five 100-mg tablets</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 5 tablets
Placebo (Atorvastatin): 1 capsule</description>
        </group>
        <group group_id="B5">
          <title>10 mg Atorvastatin</title>
          <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
Placebo (LY2484595): 5 tablets</description>
        </group>
        <group group_id="B6">
          <title>100 mg LY2484595 + 10 mg Atorvastatin</title>
          <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
LY2484595: A single 100-mg tablet
Placebo (LY2484595): 4 tablets</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="28"/>
            <count group_id="B5" value="27"/>
            <count group_id="B6" value="28"/>
            <count group_id="B7" value="165"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.6" spread="10.95"/>
                    <measurement group_id="B2" value="47.6" spread="11.94"/>
                    <measurement group_id="B3" value="49.4" spread="8.10"/>
                    <measurement group_id="B4" value="50.3" spread="9.63"/>
                    <measurement group_id="B5" value="49.4" spread="8.76"/>
                    <measurement group_id="B6" value="50.0" spread="10.01"/>
                    <measurement group_id="B7" value="49.2" spread="9.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.5" spread="14.04"/>
                    <measurement group_id="B2" value="65.9" spread="11.58"/>
                    <measurement group_id="B3" value="68.5" spread="15.71"/>
                    <measurement group_id="B4" value="69.3" spread="13.51"/>
                    <measurement group_id="B5" value="67.4" spread="12.77"/>
                    <measurement group_id="B6" value="70.3" spread="18.33"/>
                    <measurement group_id="B7" value="68.3" spread="14.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.1" spread="9.48"/>
                    <measurement group_id="B2" value="165.4" spread="9.95"/>
                    <measurement group_id="B3" value="166.5" spread="9.27"/>
                    <measurement group_id="B4" value="165.6" spread="8.56"/>
                    <measurement group_id="B5" value="166.7" spread="6.76"/>
                    <measurement group_id="B6" value="165.2" spread="8.34"/>
                    <measurement group_id="B7" value="165.7" spread="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kilograms per square meter (kg/m²)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.9" spread="3.38"/>
                    <measurement group_id="B2" value="24.0" spread="3.15"/>
                    <measurement group_id="B3" value="24.5" spread="4.10"/>
                    <measurement group_id="B4" value="25.1" spread="3.70"/>
                    <measurement group_id="B5" value="24.1" spread="3.35"/>
                    <measurement group_id="B6" value="25.5" spread="5.49"/>
                    <measurement group_id="B7" value="24.7" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-Density Lipoprotein Cholesterol (LDL-C)</title>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143.9" spread="24.02"/>
                    <measurement group_id="B2" value="143.6" spread="23.05"/>
                    <measurement group_id="B3" value="142.6" spread="30.16"/>
                    <measurement group_id="B4" value="140.1" spread="27.37"/>
                    <measurement group_id="B5" value="134.3" spread="31.78"/>
                    <measurement group_id="B6" value="139.6" spread="19.84"/>
                    <measurement group_id="B7" value="140.7" spread="26.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-Density Lipoprotein Cholesterol (HDL-C)</title>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.2" spread="12.88"/>
                    <measurement group_id="B2" value="52.1" spread="16.15"/>
                    <measurement group_id="B3" value="49.2" spread="11.41"/>
                    <measurement group_id="B4" value="50.7" spread="14.39"/>
                    <measurement group_id="B5" value="48.9" spread="13.70"/>
                    <measurement group_id="B6" value="51.7" spread="14.47"/>
                    <measurement group_id="B7" value="50.5" spread="13.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Triglycerides (TG)</title>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156.1" spread="74.31"/>
                    <measurement group_id="B2" value="133.1" spread="64.75"/>
                    <measurement group_id="B3" value="145.4" spread="79.14"/>
                    <measurement group_id="B4" value="138.9" spread="64.56"/>
                    <measurement group_id="B5" value="143.1" spread="60.02"/>
                    <measurement group_id="B6" value="144.3" spread="75.32"/>
                    <measurement group_id="B7" value="143.4" spread="69.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>millimeters of mercury (mm Hg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118.8" spread="11.75"/>
                    <measurement group_id="B2" value="117.7" spread="12.41"/>
                    <measurement group_id="B3" value="118.4" spread="12.61"/>
                    <measurement group_id="B4" value="119.5" spread="11.67"/>
                    <measurement group_id="B5" value="119.6" spread="9.82"/>
                    <measurement group_id="B6" value="116.9" spread="13.31"/>
                    <measurement group_id="B7" value="118.5" spread="11.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>millimeters of mercury (mm Hg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.7" spread="7.32"/>
                    <measurement group_id="B2" value="74.0" spread="9.57"/>
                    <measurement group_id="B3" value="74.3" spread="9.77"/>
                    <measurement group_id="B4" value="75.1" spread="7.32"/>
                    <measurement group_id="B5" value="75.4" spread="7.58"/>
                    <measurement group_id="B6" value="71.8" spread="8.52"/>
                    <measurement group_id="B7" value="74.0" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulse Rate</title>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.4" spread="8.90"/>
                    <measurement group_id="B2" value="67.7" spread="7.45"/>
                    <measurement group_id="B3" value="68.2" spread="10.41"/>
                    <measurement group_id="B4" value="67.3" spread="11.15"/>
                    <measurement group_id="B5" value="68.4" spread="8.14"/>
                    <measurement group_id="B6" value="72.4" spread="8.90"/>
                    <measurement group_id="B7" value="68.8" spread="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Atorvastatin</title>
        <description>Percent change from baseline = 100*(post-baseline assessment - baseline assessment)/baseline assessment. An increase in the percent change from baseline represented an improvement for HDL-C and a decrease in the percent change from baseline represents an improvement for LDL-C. LS mean was adjusted for baseline value of the variable analyzed.</description>
        <time_frame>Baseline, Weeks 2, 4, and 8</time_frame>
        <population>All randomized participants who took at least 1 dose of double-blind study medication, had a baseline and at least 1 post-baseline HDL-C measurement (mITT population), and had at least 1 post-baseline value of the response variable for the specified time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 30-milligram (mg) tablet</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 100-mg tablet</description>
          </group>
          <group group_id="O3">
            <title>500 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (Atorvastatin): 1 capsule
LY2484595: five 100-mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 5 tablets
Placebo (Atorvastatin): 1 capsule</description>
          </group>
          <group group_id="O5">
            <title>10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
Placebo (LY2484595): 5 tablets</description>
          </group>
          <group group_id="O6">
            <title>100 mg LY2484595 + 10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
LY2484595: A single 100-mg tablet
Placebo (LY2484595): 4 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 in Combination With Atorvastatin</title>
          <description>Percent change from baseline = 100*(post-baseline assessment - baseline assessment)/baseline assessment. An increase in the percent change from baseline represented an improvement for HDL-C and a decrease in the percent change from baseline represents an improvement for LDL-C. LS mean was adjusted for baseline value of the variable analyzed.</description>
          <population>All randomized participants who took at least 1 dose of double-blind study medication, had a baseline and at least 1 post-baseline HDL-C measurement (mITT population), and had at least 1 post-baseline value of the response variable for the specified time frame.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HDL-C, Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.30" spread="6.44"/>
                    <measurement group_id="O2" value="108.21" spread="6.45"/>
                    <measurement group_id="O3" value="122.60" spread="6.44"/>
                    <measurement group_id="O4" value="-0.73" spread="6.32"/>
                    <measurement group_id="O5" value="8.85" spread="6.45"/>
                    <measurement group_id="O6" value="101.45" spread="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C, Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.94" spread="7.62"/>
                    <measurement group_id="O2" value="122.68" spread="7.63"/>
                    <measurement group_id="O3" value="147.22" spread="7.72"/>
                    <measurement group_id="O4" value="2.09" spread="7.53"/>
                    <measurement group_id="O5" value="10.87" spread="7.62"/>
                    <measurement group_id="O6" value="117.04" spread="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C, Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.65" spread="7.95"/>
                    <measurement group_id="O2" value="130.69" spread="7.91"/>
                    <measurement group_id="O3" value="169.05" spread="8.08"/>
                    <measurement group_id="O4" value="5.19" spread="7.82"/>
                    <measurement group_id="O5" value="12.98" spread="7.91"/>
                    <measurement group_id="O6" value="116.64" spread="7.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C, Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.46" spread="3.13"/>
                    <measurement group_id="O2" value="-27.50" spread="3.14"/>
                    <measurement group_id="O3" value="-33.19" spread="3.13"/>
                    <measurement group_id="O4" value="-2.14" spread="3.07"/>
                    <measurement group_id="O5" value="-38.29" spread="3.14"/>
                    <measurement group_id="O6" value="-55.74" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C, Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.32" spread="3.14"/>
                    <measurement group_id="O2" value="-24.43" spread="3.14"/>
                    <measurement group_id="O3" value="-29.25" spread="3.18"/>
                    <measurement group_id="O4" value="2.84" spread="3.10"/>
                    <measurement group_id="O5" value="-42.23" spread="3.15"/>
                    <measurement group_id="O6" value="-52.62" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C, Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.50" spread="3.39"/>
                    <measurement group_id="O2" value="-23.56" spread="3.37"/>
                    <measurement group_id="O3" value="-25.48" spread="3.45"/>
                    <measurement group_id="O4" value="0.24" spread="3.33"/>
                    <measurement group_id="O5" value="-38.97" spread="3.38"/>
                    <measurement group_id="O6" value="-51.23" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in HDL-C at Week 2.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>92.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.04</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.65</ci_lower_limit>
            <ci_upper_limit>107.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in HDL-C at Week 4.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>106.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.69</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.47</ci_lower_limit>
            <ci_upper_limit>123.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in HDL-C at Week 8.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>103.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.18</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.14</ci_lower_limit>
            <ci_upper_limit>122.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in LDL-C at Week 2.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-17.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.39</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.73</ci_lower_limit>
            <ci_upper_limit>-10.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>The P-value is for percent change from baseline in LDL-C at Week 4.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-10.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.40</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.67</ci_lower_limit>
            <ci_upper_limit>-3.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>The P-value is for percent change from baseline in LDL-C at Week 8.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-12.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.77</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.17</ci_lower_limit>
            <ci_upper_limit>-4.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Area Under the Curve (AUC) of LY2484595 and Atorvastatin</title>
        <time_frame>Weeks 2, 4, 8, 12 (predose and postdose), and Week 16</time_frame>
        <population>Participants who were administered LY2484595 or LY2484595 + Atorvastatin and had evaluable pharmacokinetic (PK) samples.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo: 4 tablets and 1 capsule
LY2484595: A single 30-milligram (mg) tablet</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo: 4 tablets and 1 capsule
LY2484595: A single 100-mg tablet</description>
          </group>
          <group group_id="O3">
            <title>500 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (Atorvastatin): 1 capsule
LY2484595: five 100-mg tablets</description>
          </group>
          <group group_id="O4">
            <title>100 mg LY2484595 + 10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
Placebo: 4 tablets
LY2484595: A single 100-mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Area Under the Curve (AUC) of LY2484595 and Atorvastatin</title>
          <population>Participants who were administered LY2484595 or LY2484595 + Atorvastatin and had evaluable pharmacokinetic (PK) samples.</population>
          <units>nanograms*hours per milliliter (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3110" spread="32"/>
                    <measurement group_id="O2" value="8690" spread="44"/>
                    <measurement group_id="O3" value="29400" spread="42"/>
                    <measurement group_id="O4" value="8080" spread="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number and Severity of Episodes of Rashes at Any Time From Baseline Through Week 12</title>
        <description>All rash cases were adjudicated by a central dermatologist blinded to treatment assignment according to a study-specific Clinical Events Committee (CEC) charter. Rash events were assessed according to clinical relevance (severity). Categories included high risk, low risk, not a relevant dermatosis, or insufficient documentation for determination. High risk rashes included anaphylaxis, toxic epidermal necrolysis, Stevens Johnson Syndrome, Drug Reaction with Eosinophilia and System Symptoms (DRESS), urticaria/angioedema, vasculitis, erythroderma, and lupus-like reaction. All other rashes were considered low risk or not a relevant dermatosis per the Investigator's clinical opinion. A participant could be reported in multiple categories.</description>
        <time_frame>Baseline through Week 12</time_frame>
        <population>All randomized participants who took at least 1 dose of double-blind study medication intent-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks: Placebo (LY2484595): 4 tablets Placebo (Atorvastatin): 1 capsule LY2484595: A single 30-milligram (mg) tablet</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 100-mg tablet</description>
          </group>
          <group group_id="O3">
            <title>500 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (Atorvastatin): 1 capsule
LY2484595: five 100-mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 5 tablets
Placebo (Atorvastatin): 1 capsule</description>
          </group>
          <group group_id="O5">
            <title>10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
Placebo (LY2484595): 5 tablets</description>
          </group>
          <group group_id="O6">
            <title>100 mg LY2484595 + 10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
LY2484595: A single 100-mg tablet
Placebo (LY2484595): 4 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>The Number and Severity of Episodes of Rashes at Any Time From Baseline Through Week 12</title>
          <description>All rash cases were adjudicated by a central dermatologist blinded to treatment assignment according to a study-specific Clinical Events Committee (CEC) charter. Rash events were assessed according to clinical relevance (severity). Categories included high risk, low risk, not a relevant dermatosis, or insufficient documentation for determination. High risk rashes included anaphylaxis, toxic epidermal necrolysis, Stevens Johnson Syndrome, Drug Reaction with Eosinophilia and System Symptoms (DRESS), urticaria/angioedema, vasculitis, erythroderma, and lupus-like reaction. All other rashes were considered low risk or not a relevant dermatosis per the Investigator's clinical opinion. A participant could be reported in multiple categories.</description>
          <population>All randomized participants who took at least 1 dose of double-blind study medication intent-to-treat (ITT) population.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not a relevant dermatosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insufficient documentation for determination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Weeks in Blood Pressure</title>
        <description>Blood pressure reported as systolic blood pressure (SBP) and diastolic blood pressure (DBP).
LS mean was adjusted for baseline value of the variable analyzed.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who took at least 1 dose of double-blind study medication (ITT population) and had a baseline and at least 1 post-baseline value of the response variable.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 30-milligram (mg) tablet</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 100-mg tablet</description>
          </group>
          <group group_id="O3">
            <title>500 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (Atorvastatin): 1 capsule
LY2484595: five 100-mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 5 tablets
Placebo (Atorvastatin): 1 capsule</description>
          </group>
          <group group_id="O5">
            <title>10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
Placebo (LY2484595): 5 tablets</description>
          </group>
          <group group_id="O6">
            <title>100 mg LY2484595 + 10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
LY2484595: A single 100-mg tablet
Placebo (LY2484595): 4 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Weeks in Blood Pressure</title>
          <description>Blood pressure reported as systolic blood pressure (SBP) and diastolic blood pressure (DBP).
LS mean was adjusted for baseline value of the variable analyzed.</description>
          <population>All randomized participants who took at least 1 dose of double-blind study medication (ITT population) and had a baseline and at least 1 post-baseline value of the response variable.</population>
          <units>millimeters of mercury (mm Hg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="1.78"/>
                    <measurement group_id="O2" value="1.44" spread="1.76"/>
                    <measurement group_id="O3" value="4.51" spread="1.84"/>
                    <measurement group_id="O4" value="-1.39" spread="1.75"/>
                    <measurement group_id="O5" value="2.59" spread="1.76"/>
                    <measurement group_id="O6" value="2.04" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="1.07"/>
                    <measurement group_id="O2" value="0.02" spread="1.05"/>
                    <measurement group_id="O3" value="2.51" spread="1.10"/>
                    <measurement group_id="O4" value="0.68" spread="1.05"/>
                    <measurement group_id="O5" value="1.49" spread="1.05"/>
                    <measurement group_id="O6" value="0.51" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.136</p_value>
            <p_value_desc>The P-value is for change from baseline in SBP at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.50</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>7.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.257</p_value>
            <p_value_desc>The P-value is for change from baseline in SBP at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.48</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>6.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>The P-value is for change from baseline in SBP at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.54</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.70</ci_lower_limit>
            <ci_upper_limit>10.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.829</p_value>
            <p_value_desc>The P-value is for change from baseline in SBP at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.71</ci_lower_limit>
            <ci_upper_limit>3.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.603</p_value>
            <p_value_desc>The P-value is for change from baseline in DBP at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.50</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.69</ci_lower_limit>
            <ci_upper_limit>3.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.656</p_value>
            <p_value_desc>The P-value is for change from baseline in DBP at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.48</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.11</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.228</p_value>
            <p_value_desc>The P-value is for change from baseline in DBP at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.52</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.67</ci_lower_limit>
            <ci_upper_limit>4.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.516</p_value>
            <p_value_desc>The P-value is for change from baseline in DBP at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.51</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.47</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Weeks in Aldosterone</title>
        <description>LS mean was adjusted for baseline value of the variable analyzed.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who took at least 1 dose of double-blind study medication (ITT population) and had a baseline and at least 1 post-baseline aldosterone measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 30-milligram (mg) tablet</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 100-mg tablet</description>
          </group>
          <group group_id="O3">
            <title>500 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (Atorvastatin): 1 capsule
LY2484595: five 100-mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 5 tablets
Placebo (Atorvastatin): 1 capsule</description>
          </group>
          <group group_id="O5">
            <title>10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
Placebo (LY2484595): 5 tablets</description>
          </group>
          <group group_id="O6">
            <title>100 mg LY2484595 + 10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
LY2484595: A single 100-mg tablet
Placebo (LY2484595): 4 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Weeks in Aldosterone</title>
          <description>LS mean was adjusted for baseline value of the variable analyzed.</description>
          <population>All randomized participants who took at least 1 dose of double-blind study medication (ITT population) and had a baseline and at least 1 post-baseline aldosterone measurement.</population>
          <units>nanograms per deciliter (ng/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.79"/>
                    <measurement group_id="O2" value="0.37" spread="0.79"/>
                    <measurement group_id="O3" value="0.59" spread="0.84"/>
                    <measurement group_id="O4" value="0.33" spread="0.79"/>
                    <measurement group_id="O5" value="0.95" spread="0.79"/>
                    <measurement group_id="O6" value="0.62" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.513</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.11</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.57</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.970</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.12</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.82</ci_lower_limit>
            <ci_upper_limit>1.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.824</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.16</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.66</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.769</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.12</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.18</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Weeks in Plasma Renin Activity</title>
        <description>LS mean was adjusted for baseline value of the variable analyzed.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who took at least 1 dose of double-blind study medication (ITT population) and had a baseline and at least 1 post-baseline plasma renin activity measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 30-milligram (mg) tablet</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 100-mg tablet</description>
          </group>
          <group group_id="O3">
            <title>500 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (Atorvastatin): 1 capsule
LY2484595: five 100-mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 5 tablets
Placebo (Atorvastatin): 1 capsule</description>
          </group>
          <group group_id="O5">
            <title>10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
Placebo (LY2484595): 5 tablets</description>
          </group>
          <group group_id="O6">
            <title>100 mg LY2484595 + 10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
LY2484595: A single 100-mg tablet
Placebo (LY2484595): 4 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Weeks in Plasma Renin Activity</title>
          <description>LS mean was adjusted for baseline value of the variable analyzed.</description>
          <population>All randomized participants who took at least 1 dose of double-blind study medication (ITT population) and had a baseline and at least 1 post-baseline plasma renin activity measurement.</population>
          <units>nanograms per milliliter per hour</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.23"/>
                    <measurement group_id="O2" value="0.01" spread="0.24"/>
                    <measurement group_id="O3" value="-0.21" spread="0.23"/>
                    <measurement group_id="O4" value="-0.21" spread="0.23"/>
                    <measurement group_id="O5" value="-0.01" spread="0.23"/>
                    <measurement group_id="O6" value="-0.43" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.735</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.503</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.988</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.207</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.95</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Weeks in Serum Sodium</title>
        <description>LS mean was adjusted for baseline value of the variable analyzed.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who took at least 1 dose of double-blind study medication (ITT population) and had a baseline and at least 1 post-baseline serum sodium measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 30-milligram (mg) tablet</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 100-mg tablet</description>
          </group>
          <group group_id="O3">
            <title>500 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (Atorvastatin): 1 capsule
LY2484595: five 100-mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 5 tablets
Placebo (Atorvastatin): 1 capsule</description>
          </group>
          <group group_id="O5">
            <title>10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
Placebo (LY2484595): 5 tablets</description>
          </group>
          <group group_id="O6">
            <title>100 mg LY2484595 + 10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
LY2484595: A single 100-mg tablet
Placebo (LY2484595): 4 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Weeks in Serum Sodium</title>
          <description>LS mean was adjusted for baseline value of the variable analyzed.</description>
          <population>All randomized participants who took at least 1 dose of double-blind study medication (ITT population) and had a baseline and at least 1 post-baseline serum sodium measurement.</population>
          <units>milliequivalents per liter (mEq/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.31"/>
                    <measurement group_id="O2" value="-0.32" spread="0.30"/>
                    <measurement group_id="O3" value="-0.07" spread="0.32"/>
                    <measurement group_id="O4" value="-0.32" spread="0.30"/>
                    <measurement group_id="O5" value="0.35" spread="0.30"/>
                    <measurement group_id="O6" value="0.53" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.756</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.43</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.990</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.43</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.565</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.44</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.678</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.43</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Weeks in Serum Bicarbonate</title>
        <description>LS mean was adjusted for baseline value of the variable analyzed.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who took at least 1 dose of double-blind study medication (ITT population) and had a baseline and at least 1 post-baseline serum bicarbonate measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 30-milligram (mg) tablet</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 100-mg tablet</description>
          </group>
          <group group_id="O3">
            <title>500 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (Atorvastatin): 1 capsule
LY2484595: five 100-mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 5 tablets
Placebo (Atorvastatin): 1 capsule</description>
          </group>
          <group group_id="O5">
            <title>10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
Placebo (LY2484595): 5 tablets</description>
          </group>
          <group group_id="O6">
            <title>100 mg LY2484595 + 10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
LY2484595: A single 100-mg tablet
Placebo (LY2484595): 4 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Weeks in Serum Bicarbonate</title>
          <description>LS mean was adjusted for baseline value of the variable analyzed.</description>
          <population>All randomized participants who took at least 1 dose of double-blind study medication (ITT population) and had a baseline and at least 1 post-baseline serum bicarbonate measurement.</population>
          <units>milliequivalents per liter (mEq/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.43"/>
                    <measurement group_id="O2" value="0.62" spread="0.43"/>
                    <measurement group_id="O3" value="0.62" spread="0.45"/>
                    <measurement group_id="O4" value="0.52" spread="0.43"/>
                    <measurement group_id="O5" value="0.62" spread="0.43"/>
                    <measurement group_id="O6" value="1.23" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.856</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.61</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.869</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.61</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.869</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.62</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.92</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.317</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.61</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Myopathy and Liver Injury Events</title>
        <description>Myopathy events were considered muscle-related treatment emergent adverse events (TEAEs) and liver injury events were considered hepatic disorder-related TEAEs reported per Medical Dictionary for Regulatory Activities (MedDRA). An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs were newly occurring AEs or AEs worsening after first dose.</description>
        <time_frame>Baseline through Week 12</time_frame>
        <population>All randomized participants who took at least 1 dose of double-blind study medication (ITT population).</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 30-milligram (mg) tablet</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 100-mg tablet</description>
          </group>
          <group group_id="O3">
            <title>500 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (Atorvastatin): 1 capsule
LY2484595: five 100-mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 5 tablets
Placebo (Atorvastatin): 1 capsule</description>
          </group>
          <group group_id="O5">
            <title>10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
Placebo (LY2484595): 5 tablets</description>
          </group>
          <group group_id="O6">
            <title>100 mg LY2484595 + 10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
LY2484595: A single 100-mg tablet
Placebo (LY2484595): 4 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Myopathy and Liver Injury Events</title>
          <description>Myopathy events were considered muscle-related treatment emergent adverse events (TEAEs) and liver injury events were considered hepatic disorder-related TEAEs reported per Medical Dictionary for Regulatory Activities (MedDRA). An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs were newly occurring AEs or AEs worsening after first dose.</description>
          <population>All randomized participants who took at least 1 dose of double-blind study medication (ITT population).</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood creatine phosphokinase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic function abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma-glutamyltransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Highly-Sensitive C-Reactive Protein (hsCRP)</title>
        <description>LS mean was adjusted for baseline value of the variable analyzed.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who took at least 1 dose of double-blind study medication, had a baseline and at least 1 post-baseline HDL-C measurement (mITT population), and had at least 1 post-baseline hsCRP measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 30-milligram (mg) tablet</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 100-mg tablet</description>
          </group>
          <group group_id="O3">
            <title>500 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (Atorvastatin): 1 capsule
LY2484595: five 100-mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 5 tablets
Placebo (Atorvastatin): 1 capsule</description>
          </group>
          <group group_id="O5">
            <title>10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
Placebo (LY2484595): 5 tablets</description>
          </group>
          <group group_id="O6">
            <title>100 mg LY2484595 + 10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
LY2484595: A single 100-mg tablet
Placebo (LY2484595): 4 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Highly-Sensitive C-Reactive Protein (hsCRP)</title>
          <description>LS mean was adjusted for baseline value of the variable analyzed.</description>
          <population>All randomized participants who took at least 1 dose of double-blind study medication, had a baseline and at least 1 post-baseline HDL-C measurement (mITT population), and had at least 1 post-baseline hsCRP measurement.</population>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.10"/>
                    <measurement group_id="O2" value="0.00" spread="0.10"/>
                    <measurement group_id="O3" value="0.13" spread="0.09"/>
                    <measurement group_id="O4" value="-0.01" spread="0.09"/>
                    <measurement group_id="O5" value="-0.03" spread="0.10"/>
                    <measurement group_id="O6" value="0.15" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.888</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment was included in the model as fixed effects, baseline hsCRP as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.939</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment was included in the model as fixed effects, baseline hsCRP as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.296</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment was included in the model as fixed effects, baseline hsCRP as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.181</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment was included in the model as fixed effects, baseline hsCRP as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Plasma Cholesteryl Ester Transfer Protein (CETP) Activity</title>
        <description>Plasma CETP activity assay employed a fluorometric method to determine the CETP transfer activity. Percent change from baseline = 100*(post-baseline assessment - baseline assessment)/baseline assessment. An increase in the percent change from baseline represented an improvement. LS mean was adjusted for baseline value of the variable analyzed.</description>
        <time_frame>Baseline, Weeks 4, 8, and 12</time_frame>
        <population>All randomized participants who took at least 1 dose of double-blind study medication, had a baseline and at least 1 post-baseline HDL-C measurement (mITT population), and had at least 1 post-baseline CETP activity measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 30-milligram (mg) tablet</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 100-mg tablet</description>
          </group>
          <group group_id="O3">
            <title>500 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (Atorvastatin): 1 capsule
LY2484595: five 100-mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 5 tablets
Placebo (Atorvastatin): 1 capsule</description>
          </group>
          <group group_id="O5">
            <title>10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
Placebo (LY2484595): 5 tablets</description>
          </group>
          <group group_id="O6">
            <title>100 mg LY2484595 + 10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
LY2484595: A single 100-mg tablet
Placebo (LY2484595): 4 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Plasma Cholesteryl Ester Transfer Protein (CETP) Activity</title>
          <description>Plasma CETP activity assay employed a fluorometric method to determine the CETP transfer activity. Percent change from baseline = 100*(post-baseline assessment - baseline assessment)/baseline assessment. An increase in the percent change from baseline represented an improvement. LS mean was adjusted for baseline value of the variable analyzed.</description>
          <population>All randomized participants who took at least 1 dose of double-blind study medication, had a baseline and at least 1 post-baseline HDL-C measurement (mITT population), and had at least 1 post-baseline CETP activity measurement.</population>
          <units>percent change in CETP activity</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.62" spread="4.23"/>
                    <measurement group_id="O2" value="-75.26" spread="4.30"/>
                    <measurement group_id="O3" value="-89.14" spread="4.38"/>
                    <measurement group_id="O4" value="1.67" spread="4.22"/>
                    <measurement group_id="O5" value="-1.33" spread="4.22"/>
                    <measurement group_id="O6" value="-68.58" spread="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.91" spread="4.47"/>
                    <measurement group_id="O2" value="-76.23" spread="4.40"/>
                    <measurement group_id="O3" value="-90.97" spread="4.57"/>
                    <measurement group_id="O4" value="2.70" spread="4.32"/>
                    <measurement group_id="O5" value="-4.89" spread="4.32"/>
                    <measurement group_id="O6" value="-79.90" spread="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.07" spread="3.57"/>
                    <measurement group_id="O2" value="-73.86" spread="3.55"/>
                    <measurement group_id="O3" value="-85.30" spread="3.69"/>
                    <measurement group_id="O4" value="9.22" spread="3.49"/>
                    <measurement group_id="O5" value="-5.69" spread="3.54"/>
                    <measurement group_id="O6" value="-73.38" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in plasma CETP activity at Week 4.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-43.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.97</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.16</ci_lower_limit>
            <ci_upper_limit>-33.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in plasma CETP activity at Week 4.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-76.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.02</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-86.89</ci_lower_limit>
            <ci_upper_limit>-66.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in plasma CETP activity at Week 4.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-90.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.08</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-100.87</ci_lower_limit>
            <ci_upper_limit>-80.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in plasma CETP activity at Week 4.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-67.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.96</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-77.12</ci_lower_limit>
            <ci_upper_limit>-57.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in plasma CETP activity at Week 8.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-42.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.21</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.88</ci_lower_limit>
            <ci_upper_limit>-32.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in plasma CETP activity at Week 8.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-78.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.17</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-89.15</ci_lower_limit>
            <ci_upper_limit>-68.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in plasma CETP activity at Week 8.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-93.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.29</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-104.08</ci_lower_limit>
            <ci_upper_limit>-83.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in plasma CETP activity at Week 8.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-75.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.31</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-85.46</ci_lower_limit>
            <ci_upper_limit>-64.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in plasma CETP activity at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-50.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.98</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.53</ci_lower_limit>
            <ci_upper_limit>-42.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in plasma CETP activity at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-83.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.98</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-91.32</ci_lower_limit>
            <ci_upper_limit>-74.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in plasma CETP activity at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-94.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.08</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-102.92</ci_lower_limit>
            <ci_upper_limit>-86.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in plasma CETP activity at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-67.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.15</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-76.20</ci_lower_limit>
            <ci_upper_limit>-59.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma CETP Mass</title>
        <description>Plasma CETP mass assay was a solid-phase enzyme-linked immunosorbent assay (ELISA) designated to measure human CETP mass which employed the quantitative enzyme immunoassay principle. An increase in plasma CETP mass represented an improvement. LS mean was adjusted for baseline value of the variable analyzed.</description>
        <time_frame>Baseline, Weeks 4, 8, and 12</time_frame>
        <population>All randomized participants who took at least 1 dose of double-blind study medication, had a baseline and at least 1 post-baseline HDL-C measurement (mITT population), and had at least 1 post-baseline CETP mass measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 30-milligram (mg) tablet</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 100-mg tablet</description>
          </group>
          <group group_id="O3">
            <title>500 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (Atorvastatin): 1 capsule
LY2484595: five 100-mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 5 tablets
Placebo (Atorvastatin): 1 capsule</description>
          </group>
          <group group_id="O5">
            <title>10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
Placebo (LY2484595): 5 tablets</description>
          </group>
          <group group_id="O6">
            <title>100 mg LY2484595 + 10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
LY2484595: A single 100-mg tablet
Placebo (LY2484595): 4 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma CETP Mass</title>
          <description>Plasma CETP mass assay was a solid-phase enzyme-linked immunosorbent assay (ELISA) designated to measure human CETP mass which employed the quantitative enzyme immunoassay principle. An increase in plasma CETP mass represented an improvement. LS mean was adjusted for baseline value of the variable analyzed.</description>
          <population>All randomized participants who took at least 1 dose of double-blind study medication, had a baseline and at least 1 post-baseline HDL-C measurement (mITT population), and had at least 1 post-baseline CETP mass measurement.</population>
          <units>micrograms per milliliter (µg/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.18"/>
                    <measurement group_id="O2" value="3.14" spread="0.18"/>
                    <measurement group_id="O3" value="3.54" spread="0.18"/>
                    <measurement group_id="O4" value="0.08" spread="0.18"/>
                    <measurement group_id="O5" value="-0.28" spread="0.18"/>
                    <measurement group_id="O6" value="1.94" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.21"/>
                    <measurement group_id="O2" value="3.09" spread="0.21"/>
                    <measurement group_id="O3" value="4.02" spread="0.22"/>
                    <measurement group_id="O4" value="0.10" spread="0.21"/>
                    <measurement group_id="O5" value="-0.21" spread="0.21"/>
                    <measurement group_id="O6" value="1.83" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.21"/>
                    <measurement group_id="O2" value="2.96" spread="0.21"/>
                    <measurement group_id="O3" value="3.36" spread="0.22"/>
                    <measurement group_id="O4" value="0.13" spread="0.21"/>
                    <measurement group_id="O5" value="-0.19" spread="0.21"/>
                    <measurement group_id="O6" value="1.95" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for change from baseline in plasma CETP mass at Week 4.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.25</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.38</ci_lower_limit>
            <ci_upper_limit>2.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for change from baseline in plasma CETP mass at Week 4.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.25</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.65</ci_lower_limit>
            <ci_upper_limit>3.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for change from baseline in plasma CETP mass at Week 4.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.25</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.04</ci_lower_limit>
            <ci_upper_limit>3.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for change from baseline in plasma CETP mass at Week 4.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.25</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.81</ci_lower_limit>
            <ci_upper_limit>2.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for change from baseline in plasma CETP mass at Week 8.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.40</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for change from baseline in plasma CETP mass at Week 8.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.51</ci_lower_limit>
            <ci_upper_limit>3.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for change from baseline in plasma CETP mass at Week 8.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.30</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.42</ci_lower_limit>
            <ci_upper_limit>4.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for change from baseline in plasma CETP mass at Week 8.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.56</ci_lower_limit>
            <ci_upper_limit>2.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for change from baseline in plasma CETP mass at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.34</ci_lower_limit>
            <ci_upper_limit>2.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for change from baseline in plasma CETP mass at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.34</ci_lower_limit>
            <ci_upper_limit>3.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for change from baseline in plasma CETP mass at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.30</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.74</ci_lower_limit>
            <ci_upper_limit>3.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for change from baseline in plasma CETP mass at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.65</ci_lower_limit>
            <ci_upper_limit>2.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline to 12 Weeks in High Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 and Placebo</title>
        <description>Percent change from baseline = 100*(post-baseline assessment - baseline assessment)/baseline assessment. Higher values in the percent change from baseline represented an improvement for HDL-C and lower values in the percent change from baseline represented an improvement for LDL-C. Least Squares (LS) mean was adjusted for baseline value of the variable analyzed.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All randomized participants who took at least 1 dose of double-blind study medication, had a baseline and at least 1 post-baseline HDL-C measurement [modified intent-to-treat (mITT) population], and also completed the Week 12 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 30-milligram (mg) tablet</description>
          </group>
          <group group_id="O2">
            <title>100 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 100-mg tablet</description>
          </group>
          <group group_id="O3">
            <title>500 mg LY2484595</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (Atorvastatin): 1 capsule
LY2484595: five 100-mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 5 tablets
Placebo (Atorvastatin): 1 capsule</description>
          </group>
          <group group_id="O5">
            <title>10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
Placebo (LY2484595): 5 tablets</description>
          </group>
          <group group_id="O6">
            <title>100 mg LY2484595 + 10 mg Atorvastatin</title>
            <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
LY2484595: A single 100-mg tablet
Placebo (LY2484595): 4 tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to 12 Weeks in High Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 and Placebo</title>
          <description>Percent change from baseline = 100*(post-baseline assessment - baseline assessment)/baseline assessment. Higher values in the percent change from baseline represented an improvement for HDL-C and lower values in the percent change from baseline represented an improvement for LDL-C. Least Squares (LS) mean was adjusted for baseline value of the variable analyzed.</description>
          <population>All randomized participants who took at least 1 dose of double-blind study medication, had a baseline and at least 1 post-baseline HDL-C measurement [modified intent-to-treat (mITT) population], and also completed the Week 12 visit.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.22" spread="8.97"/>
                    <measurement group_id="O2" value="123.35" spread="8.92"/>
                    <measurement group_id="O3" value="143.56" spread="9.16"/>
                    <measurement group_id="O4" value="8.00" spread="8.83"/>
                    <measurement group_id="O5" value="17.35" spread="8.91"/>
                    <measurement group_id="O6" value="120.60" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.23" spread="3.46"/>
                    <measurement group_id="O2" value="-22.13" spread="3.43"/>
                    <measurement group_id="O3" value="-20.95" spread="3.55"/>
                    <measurement group_id="O4" value="1.24" spread="3.40"/>
                    <measurement group_id="O5" value="-37.66" spread="3.44"/>
                    <measurement group_id="O6" value="-52.29" spread="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparisons between LY2484595 and Placebo were the primary focus for this endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in HDL-C at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>74.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.59</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>53.38</ci_lower_limit>
            <ci_upper_limit>95.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparisons between LY2484595 and Placebo were the primary focus for this endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in HDL-C at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>115.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.55</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.58</ci_lower_limit>
            <ci_upper_limit>136.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparisons between LY2484595 and Placebo were the primary focus for this endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in HDL-C at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>135.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.72</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>114.50</ci_lower_limit>
            <ci_upper_limit>156.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparisons between LY2484595 and Placebo were the primary focus for this endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>The P-value is for percent change from baseline in LDL-C at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-15.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.85</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.50</ci_lower_limit>
            <ci_upper_limit>-7.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparisons between LY2484595 and Placebo were the primary focus for this endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in LDL-C at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-23.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.83</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.37</ci_lower_limit>
            <ci_upper_limit>-15.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparisons between LY2484595 and Placebo were the primary focus for this endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in LDL-C at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-22.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.91</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.32</ci_lower_limit>
            <ci_upper_limit>-14.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The P-value is for percent change from baseline in HDL-C at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>103.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.64</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.32</ci_lower_limit>
            <ci_upper_limit>124.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>The P-value is for percent change from baseline in LDL-C at Week 12.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Treatment, visit, and treatment by visit interaction were included in the model as fixed effects, baseline measurement as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-14.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.88</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.72</ci_lower_limit>
            <ci_upper_limit>-6.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>30 mg LY2484595</title>
          <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule LY2484595: A single 30-mg tablet</description>
        </group>
        <group group_id="E2">
          <title>100 mg LY2484595</title>
          <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 4 tablets
Placebo (Atorvastatin): 1 capsule
LY2484595: A single 100-mg tablet</description>
        </group>
        <group group_id="E3">
          <title>500 mg LY2484595</title>
          <description>The following were administered orally once daily for 12 weeks:
Placebo (Atorvastatin): 1 capsule
LY2484595: five 100-mg tablets</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>The following were administered orally once daily for 12 weeks:
Placebo (LY2484595): 5 tablets
Placebo (Atorvastatin): 1 capsule</description>
        </group>
        <group group_id="E5">
          <title>10 mg Atorvastatin</title>
          <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
Placebo (LY2484595): 5 tablets</description>
        </group>
        <group group_id="E6">
          <title>100 mg LY2484595 + 10 mg Atorvastatin</title>
          <description>The following were administered orally once daily for 12 weeks:
Atorvastatin: A single 10-mg capsule
LY2484595: A single 100-mg tablet
Placebo (LY2484595): 4 tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Traumatic lung injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Periproctitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

